5-(p-Fluorphenyl)-2-hydroxy-3-methylbenzoesaeure | 22494-36-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(p-Fluorphenyl)-2-hydroxy-3-methylbenzoesaeure
• 英文别名: 4a(2)-Fluoro-4-hydroxy-5-methyl[1,1a(2)-biphenyl]-3-carboxylic acid；5-(4-fluorophenyl)-2-hydroxy-3-methylbenzoic acid
• CAS: 22494-36-6
• 化学式: C₁₄H₁₁FO₃
• 分子量: 246.238
• InChiKey: PXQNHLSBUFXIRN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-氟-4-羟基-联苯-3-羧酸 在 sodium hydroxide 、 lithium aluminium tetrahydride 、 硫酸 、 potassium carbonate 作用下， 以 乙醚 、 乙醇 为溶剂， 生成 5-(p-Fluorphenyl)-2-hydroxy-3-methylbenzoesaeure
  参考文献：
  名称：

  Novel analgesic-antiinflammatory salicylates

  摘要：

  5-(2,4-Difluorophenyl)salicylic acid, diflunisal (25), is the best compound, in terms of both efficacy and safety, from over 500 salicylates investigated in our laboratories. It is a chemically distinct, nonacetylating salicylic acid, more active than aspirin as an analgesic and antiinflammatory agent and superior in duration of action and therapeutic index. Some recent clinical and biochemical observations are briefly discussed.

  DOI：

  10.1021/jm00209a001

文献信息

• Methods and reagents for the treatment of metabolic disorders
  申请人：Lee S. Margaret

  公开号：US20060069161A1

  公开（公告）日：2006-03-30

  The invention features compositions, methods, and kits for the treatment of metabolic disorders such as diabetes and obesity.

  本发明的特点是用于治疗糖尿病和肥胖症等代谢性疾病的组合物、方法和试剂盒。
• TOPICAL USE OF HALOSALICYLIC ACID DERIVATIVES
  申请人：AVON PRODUCTS, INC.

  公开号：EP1694337A2

  公开（公告）日：2006-08-30
• EP1781303A4
  申请人：——

  公开号：EP1781303A4

  公开（公告）日：2008-07-02
• METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS
  申请人：CombinatoRx, Incorporated

  公开号：EP1781303A1

  公开（公告）日：2007-05-09
• Topical use of halosalicylic acid derivatives
  申请人：McKie B. Derrick

  公开号：US20050136015A1

  公开（公告）日：2005-06-23

  Halosalicylic acid compounds of the present invention, having at least one halogen substituent on the aromatic ring, are employed to produce desquamation of skin, treat nail disorders or dandruff, remove calluses, control acne and excess sebum production, reduce skin pore size or control blackheads. Topical compositions containing the halosalicylic acid compound and a cosmetically acceptable vehicle are disclosed.